×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Acurx Pharmaceuticals, Inc. Rings the Closing Bell
Nasdaq
About This Event Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), a late-stage biopharmaceutical company developing a new class of small molecule...
1 month ago
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript
Seeking Alpha
Acurx Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ACXP) Q1 2024 Earnings Conference Call May 15, 2024 8:00 AM ETCompany ParticipantsRobert Shawah...
3 weeks ago
Why Is Antibiotic Player Acurx Pharmaceuticals Stock Trading Lower Today?
Yahoo Finance
Acurx Pharmaceuticals Inc (NASDAQ:ACXP) released comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic...
4 months ago
Acurx Pharmaceuticals Inc Down 1.84% To $2.67 After Earnings Miss
InvestorsObserver
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria...
2 months ago
Acurx Pharmaceuticals Reports First Quarter 2024 Results and Provides Business Update
citybiz
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a clinical stage biopharmaceutical company developing a new class of antibiotics for...
3 weeks ago
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call Transcript
Insider Monkey
Operator: Greetings and welcome to the Acurx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Earnings Results and Business Update...
2 months ago
Will novel antibiotic become front-line for C. difficile?
European Pharmaceutical Review
Based on positive Phase II data, first-in-class antibiotic candidate ibezapolstat for C. difficile is expected to advance to Phase III...
8 months ago
Acurx's ibezapolstat posts positive phase II data but stock slips
BioWorld MedTech
Acurx Pharmaceuticals Inc. continues to post positive data for its lead candidate ibezapolstat but that didn't stop the stock from tumbling.
4 months ago
Acurx gears up for Phase 3 trials of CDI antibiotic candidate
Investing.com
STATEN ISLAND, N.Y. - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a biopharmaceutical company specializing in the development of new...
3 weeks ago
Acurx reports results from meeting with FDA regarding ibezapolstat
TipRanks
Acurx Pharmaceuticals announced the successful outcome of an End-of-Phase 2 meeting with the FDA supporting the advancement of ibezapolstat...
2 weeks ago